Dollar rebounds despite Fed independence worries; euro slips
Investing.com -- Femasys Inc. (NASDAQ:FEMY) stock plunged 36.7% after the women’s health biomedical company announced the pricing of an underwritten public offering at a significant discount to its previous trading price.
The company priced its public offering of 10,434,586 shares of common stock at $0.36 per share, along with pre-funded warrants to purchase up to 11,750,000 shares. The offering also includes accompanying common warrants to purchase up to an aggregate of 22,184,586 shares. A small portion of 87,363 shares were sold to certain company officers at a higher price of $0.5151 per share.
Femasys expects to raise approximately $8.0 million in gross proceeds from the offering, which is expected to close around August 27, 2025. The company plans to use the proceeds to expand commercial efforts, develop its products and product candidates, and for general corporate purposes including capital expenditures and working capital.
The offering is being managed by Jones and Laidlaw & Company (UK) Ltd. as joint book-running managers.
Femasys focuses on developing accessible, in-office therapeutic and diagnostic products for women’s health. The significant price drop reflects investor reaction to the dilutive offering and the discounted pricing compared to the company’s previous market valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.